Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Endocrinol (Oxf) ; 54(6): 731-8, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11422107

RESUMO

OBJECTIVE: The aims of the study were: (1) to assess dopaminergic tone in a group of HIV infected men and the bioactivity and the molecular species of their circulating PRL in comparison with healthy men and (2) to search for a correlation between serum PRL and CD4+ T lymphocytes and viral load. DESIGN: In a cross-sectional study the effect of acute dopaminergic blockade with intravenous metoclopramide on serum PRL (both immunoreactive and biologically active), TSH and PRL circulating molecular isoforms was evaluated. PATIENTS: Twenty untreated HIV infected men category C2 or C3, mean (SD) age 26.9 (6.3) years, were compared to 14 clinically healthy HIV-negative men, age 25.4 (2.3) years. MEASUREMENTS: Under fasting conditions and following metoclopramide administration duplicate measurements of serum immunoreactive PRL, bioactive PRL (PRL dependent Nb2 lymphoma cell assay) and immunoreactive TSH were performed. The molecular species of circulating PRL were determined by immunoblot analysis, CD4+ T lymphocytes by flow cytometry and the viral load using a nucleic acid sequence-based amplification assay. RESULTS: In HIV infected men fasting bioactive (but not immunoreactive) PRL was higher (P = 0.03), but the stimulated PRL (both immunoreactive and bioactive) was lower than in healthy men throughout the test (P < or = 0.01). Fasting serum TSH was similar in HIV-infected and healthy men while its response to metoclopramide was absent in the former but not in the latter (P = 0.049). A 23.5-kD PRL was the predominant circulating isoform both in patients and healthy men. Considering HIV-infected and healthy men, CD4+ T lymphocytes correlated negatively with fasting bioactive PRL (P = 0.008) and positively with the area under the PRL (both immunoreactive and bioactive) curves (P < 0.001). The viral load was negatively correlated with the area under the curve of the bioactive/immunoreactive ratio (P = 0.008). CONCLUSIONS: The raised fasting bioactive PRL, the diminished response of both immunoreactive and bioactive PRL and the absent TSH response to metoclopramide in HIV infected men, suggest the existence of a decreased, but not absent dopaminergic tone. A monomeric form of PRL was the predominant circulating species, as in healthy men, and this hormone seems to be associated both with CD4+ T lymphocytes and the viral load.


Assuntos
Antagonistas de Dopamina , Infecções por HIV/metabolismo , Metoclopramida , Prolactina/sangue , Adulto , Área Sob a Curva , Contagem de Linfócito CD4 , Estudos de Casos e Controles , Estudos Transversais , Citometria de Fluxo , Infecções por HIV/virologia , Humanos , Immunoblotting , Masculino , Isoformas de Proteínas/sangue , Análise de Regressão , Tireotropina/sangue , Carga Viral
2.
Endocr Pract ; 6(3): 244-8, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11421539

RESUMO

OBJECTIVE: To search for differences in the frequency of thyroid peroxidase antibodies (TPO-Ab) among 150 pregnant Mexican women who were healthy, had type 2 diabetes mellitus (DM), or had gestational diabetes mellitus (GDM). METHODS: Fifty healthy women, 50 women with type 2 DM, and 50 women with GDM were studied at delivery. In addition, 142 of their offspring were included in the study. TPO-Ab were determined by enzyme immunoassay, and total triiodothyronine, free thyroxine, and thyroid-stimulating hormone (thyrotropin) were measured by radioimmunoanalysis. RESULTS: TPO-Ab were < or = 70 U/mL (negative) in 50% of the healthy women and in 60% and 60% of women with type 2 DM and GDM, respectively (no significant difference). TPO-Ab were 71 to 250 U/mL (slightly positive) in 40% of healthy women and in 30% and 34% of women with type 2 DM and GDM, respectively (no significant difference). TPO-Ab were > or =251 U/mL (strongly positive) in 10% of healthy women and in 10% and 6% of women with type 2 DM and GDM, respectively. One healthy woman had subclinical hypothyroidism, and the rest were euthyroid. The newborn offspring of these Mexican women were euthyroid and had similar frequencies of TPO-Ab (all had TPO-Ab <250 U/mL). CONCLUSION: (1) The frequency of TPO-Ab > or =251 U/mL was similar in pregnant Mexican women with GDM in comparison with those who were healthy or had type 2 DM. (2) The similar high frequencies of slightly positive TPO-Ab in the three groups of pregnant women can partially be explained by the existence of an ethnic factor, the very strong family history of DM in a substantial percentage of them, and the use of a more sensitive and specific assay for detection of TPO-Ab.


Assuntos
Autoanticorpos/análise , Diabetes Mellitus Tipo 2/enzimologia , Diabetes Gestacional/enzimologia , Iodeto Peroxidase/imunologia , Adulto , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Gestacional/epidemiologia , Feminino , Seguimentos , Humanos , Técnicas Imunoenzimáticas , Recém-Nascido , México/epidemiologia , Gravidez , Testes de Função Tireóidea , Hormônios Tireóideos/sangue
3.
J Lab Clin Med ; 133(1): 70-4, 1999 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10385484

RESUMO

To investigate whether metoclopramide-induced prolactin release is impaired in HIV-infected men, we studied 10 clinically healthy HIV-negative adult men (group 1) and 10 consecutive HIV-positive adult men (group 2) with anti-HIV antibodies confirmed by Western blot analysis and a CD4 cell count from 13 to 570x10(6)/L. After a 10- to 12-hour overnight fast, three basal blood samples were obtained at 15-minute intervals (-30, -15, and 0 minutes) and thereafter at 15, 30, 60, 90, 120, 180, and 240 minutes after a 10-mg intravenous bolus of metoclopramide. Duplicate serum prolactin concentrations were measured in each sample with commercially available radioimmunoassay kits. No significant differences between groups were observed in basal prolactin levels. Group 2 had lower serum prolactin concentrations than group 1 throughout the test (P< or =.002). The area under the prolactin curve (mean +/- SD) was also lower in group 2 than in group 1 (7156+/-1433 ng/mL/240 min vs. 12430+/-2454 ng/mL/240 min, P<.0001), and the area under the prolactin curve had a significant correlation with the CD4 cell counts (r = 0.7912, P<.001). These findings suggest that the hypothalamic dopaminergic tone, although present, was clearly diminished in these HIV-positive men regardless of their clinical stage.


Assuntos
Antagonistas de Dopamina/farmacologia , Infecções por HIV/sangue , Metoclopramida/farmacologia , Hipófise/efeitos dos fármacos , Prolactina/sangue , Adulto , Área Sob a Curva , Contagem de Linfócito CD4 , Soronegatividade para HIV , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Hipófise/metabolismo , Radioimunoensaio , Kit de Reagentes para Diagnóstico
4.
Med Hypotheses ; 53(5): 425-8, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10616045

RESUMO

The possible role of prolactin (PRL) in human immunodeficiency virus (HIV) infection is unknown, despite the modulatory role of this hormone in humoral and cell-mediated immune responses. Recent studies have evidenced: (a) intralymphocyte synthesis of dopamine (DA) which down-regulates their own proliferation and differentiation; (b) decreased DA but increased PRL concentrations in cerebrospinal fluid of HIV-infected men; and (c) diminished hypothalamic DA tone in HIV-infected men. The present hypothesis proposes that, in HIV-infected men, a diminished generalized DA tone exists to stimulate human lymphocyte proliferation and differentiation at a maximum possible rate by: (1) decreasing the inhibitory influence of intralymphocyte DA; and (2) maintaining pituitary and extrapituitary (i.e. lymphocyte) PRL synthesis and release as high as possible. If this hypothesis is correct, it may have a potentially important therapeutic implication: the possibility to rebuild the battered immune system in HIV-infected patients from inside the body in a physiologic manner by the parenteral administration of recombinant human PRL.


Assuntos
Linfócitos T CD4-Positivos/fisiologia , Infecções por HIV/fisiopatologia , Prolactina/fisiologia , Linfócitos T CD4-Positivos/metabolismo , Dopamina/biossíntese , Infecções por HIV/líquido cefalorraquidiano , Infecções por HIV/metabolismo , Humanos , Modelos Biológicos , Prolactina/administração & dosagem , Prolactina/líquido cefalorraquidiano , Proteínas Recombinantes/administração & dosagem
5.
Ginecol Obstet Mex ; 65: 523-8, 1997 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-9477648

RESUMO

Antiphospholipid Antibodies has been associated with severe maternal and fetal sequels, like recurrent miscarriage, death, intrauterine growth retardation, pregnancy-induced hypertensive disease, thromboembolic phenomena and thrombocytopenia. Pathogenesis has been explained reporting that IgG from women with antiphospholipid antibodies increases placenta thromboxane production without affecting prostacyclin production, which conducts to thrombosis of placenta uterus junction. In 1982, it was suggested for the first time low doses of aspirin and prednisone for treatment of recurrent fetal death associated to this syndrome, heparin therapy was reported in 1984, recommended a doses of 15,000 U/day during first pregnancy trimester and 20,000 U/day posteriorly. The objective of this report, is the description a clinic case of a patient with recurrent fetal death and antiphospholipid antibodies syndrome, discussing a prenatal and obstetric treatment model, including diagnosis and final therapeutic, which includes the participation of some other specialists, the national experience in diagnosis and treatment is initial, and also because it has been reported a rate of fetal death in those patient with no treatment, almost of 90%. The importance of identify this syndrome is not based on its prevalence but on its maternal complications and that it is a cause of fetal death potentially treatable.


Assuntos
Síndrome Antifosfolipídica , Morte Fetal/etiologia , Complicações na Gravidez , Adulto , Anti-Inflamatórios/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Síndrome Antifosfolipídica/diagnóstico , Síndrome Antifosfolipídica/terapia , Aspirina/uso terapêutico , Feminino , Morte Fetal/prevenção & controle , Humanos , Recém-Nascido , Masculino , Prednisona/uso terapêutico , Gravidez , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/terapia , Recidiva
6.
Rev Invest Clin ; 25(4): 373-8, 1973.
Artigo em Espanhol | MEDLINE | ID: mdl-4764557

Assuntos
Linfócitos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA